Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine

The Journal of Infectious Diseases
Yushi YaoZhou Xing

Abstract

The translation of preclinically promising novel tuberculosis vaccines to ultimate human applications has been challenged by the lack of animal models with an immune system equivalent to the human immune system in its genetic diversity and level of susceptibility to tuberculosis. We have developed a humanized mice (Hu-mice) tuberculosis model system to investigate the clinical relevance of a novel virus-vectored (VV) tuberculosis vaccine administered via respiratory mucosal or parenteral route. We find that VV vaccine activates T cells in Hu-mice as it does in human vaccinees. The respiratory mucosal route for delivery of VV vaccine in Hu-mice, but not the parenteral route, significantly reduces the humanlike lung tuberculosis outcomes in a human T-cell-dependent manner. Our results suggest that the Hu-mouse can be used to predict the protective efficacy of novel tuberculosis vaccines/strategies before they proceed to large, expensive human trials. This new vaccine testing system will facilitate the global pace of clinical tuberculosis vaccine development.

References

Dec 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R E HuebnerJ B Bass
Nov 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jun WangZhou Xing
Aug 4, 2009·Current Opinion in Immunology·Andrea M Cooper
Jun 15, 2010·Trends in Immunology·Mangalakumari JeyanathanZhou Xing
Apr 1, 2011·Mucosal Immunology·K B UrdahlJ D Ernst
Mar 28, 2012·Tuberculosis·Michael J Brennan, Jelle Thole
Feb 6, 2013·Proceedings of the National Academy of Sciences of the United States of America·Tal ShayUNKNOWN ImmGen Consortium
Apr 6, 2013·Proceedings of the National Academy of Sciences of the United States of America·Frank HeutsMartin E Rottenberg
May 17, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Thomas LindenstrømPeter Andersen
May 22, 2013·PloS One·Veronica E CalderonJanice J Endsley
Jun 12, 2013·Current Opinion in Immunology·Michael A BrehmLeonard D Shultz
Aug 6, 2013·European Journal of Immunology·Carol LeungChristian Münz
Nov 21, 2013·Mucosal Immunology·P C L BeverleyE Z Tchilian
Feb 25, 2014·Current Opinion in Immunology·Stefan H E KaufmannGiuseppe Del Giudice
Feb 28, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joshua S WoodworthPeter Andersen
May 6, 2014·Frontiers in Immunology·Teresa PrezzemoloNadia Caccamo
Jun 4, 2014·Cold Spring Harbor Perspectives in Medicine·Peter Andersen, Stefan H E Kaufmann
Sep 3, 2014·Chest·Zhou XingFiona Smaill
Jan 16, 2015·Clinical and Vaccine Immunology : CVI·Kamlesh BhattPadmini Salgame
May 29, 2015·The New England Journal of Medicine·Haileyesus GetahunMario Raviglione
Jun 16, 2015·Expert Opinion on Drug Discovery·Henna MyllymäkiMika Rämet
Jan 27, 2016·Human Vaccines & Immunotherapeutics·Matthew K O'Shea, Helen McShane
Feb 26, 2016·Scientific Reports·Rebecca J NusbaumJanice J Endsley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.